BrightGene posts strong Phase II results for dual‑agonist drug

25 June 2025

BrightGene Pharmaceutical unveiled promising mid‑stage results for its investigational treatment BGM0504 at the American Diabetes Association conference, challenging established competitors in metabolic disease.

Analysts took note of significant improvements over current GLP‑1 therapies in glycaemic control and weight reduction, alongside robust safety data. Attention now turns to an ongoing head‑to‑head obesity trial versus Eli Lilly’s (NYSE: LLY) tirzepatide.

Obesity and type 2 diabetes

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical